


## AMENDMENTS TO THE CLAIMS

### IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application. Please amend the claims as follows.

1. (Currently Amended) A compound of Formula (I):



wherein

a and b are, independently, equal to 0, 1, or 2, wherein the values of 0, 1, and 2 represents a direct bond,  $\text{CH}_2$ , and  $\text{CH}_2\text{CH}_2$ , respectively, and wherein the  $\text{CH}_2$  and  $\text{CH}_2\text{CH}_2$  groups are optionally substituted 1 to 2 times with a substituent group, wherein said substituent group(s) are selected from the group consisting of: alkyl, aryl, alkylene-aryl, arylene-alkyl, alkylene-arylene-alkyl, O-alkyl, O-aryl, and hydroxyl;

W is  $\text{O}$ ,  $\text{S}$ , or  $\text{N}(\text{R}_2)$ ,

wherein

$\text{R}_2$  is

- a) -hydrogen;
- b) -alkyl;
- c)  $-\text{L}_3\text{-D-G}$
- d)  $-\text{L}_3\text{-D-alkyl}$ :

- e) – L<sub>3</sub>-D-aryl;
- f) – L<sub>3</sub>-D-heteroaryl;
- g) – L<sub>3</sub>-D-cycloalkyl;
- h) – L<sub>3</sub>-D-heterocyclyl;
- i) – L<sub>3</sub>-D-arylene-alkyl;
- j) – L<sub>3</sub>-D-alkylene-arylene-alkyl;
- k) – L<sub>3</sub>-D-alkylene-aryl;
- l) – L<sub>3</sub>-D-alkyl-G;
- m) – L<sub>3</sub>-D-aryl-G;
- n) – L<sub>3</sub>-D-heteroaryl-G;
- o) – L<sub>3</sub>-D-cycloalkyl-G;
- p) – L<sub>3</sub>-D-heterocyclyl-G;
- q) – L<sub>3</sub>-D-arylene-alkyl-G;
- r) – L<sub>3</sub>-D-alkylene-arylene-alkyl-G; or
- s) – L<sub>3</sub>-D-alkylene-aryl-G;

wherein


L<sub>3</sub> is a direct bond, –alkylene, –alkenylene, or alkynylene;

D is a direct bond, –CH<sub>2</sub>–, –O–, –N(R<sub>5</sub>)–, –C(O)–, –CON(R<sub>5</sub>)–, –N(R<sub>6</sub>)C(O)–, –N(R<sub>6</sub>)CON(R<sub>5</sub>)–, –N(R<sub>5</sub>)C(O)O–, –OC(O)N(R<sub>5</sub>)–, –N(R<sub>5</sub>)SO<sub>2</sub>–, –SO<sub>2</sub>N(R<sub>5</sub>)–, –C(O)–O–, –O–C(O)–, –S–, –S(O)–, –S(O<sub>2</sub>)–, or –N(R<sub>5</sub>)SO<sub>2</sub>N(R<sub>6</sub>)–, –N=N–, or –N(R<sub>5</sub>)–N(R<sub>6</sub>)–;

wherein

R<sub>5</sub> and R<sub>6</sub> are independently selected from the group consisting of: –hydrogen, –alkyl, –aryl, –arylene-alkyl, –alkylene-aryl, and –alkylene-arylene-alkyl; and


G is hydrogen,  $-\text{CN}$ ,  $-\text{SO}_3\text{H}$ ,  $-\text{P}(\text{O})(\text{OH})_2$ ,  $-\text{P}(\text{O})(\text{O-alkyl})(\text{OH})$ ,  $-\text{CO}_2\text{H}$ ,



$-\text{CO}_2\text{-alkyl}$ , an acid isostere,  $-\text{NR}_7\text{R}_8$ , or ;

wherein

$\text{R}_7$  and  $\text{R}_8$  are independently selected from the group consisting of:  
 hydrogen, -alkyl,  $-\text{L}_4\text{-E-alkyl}$ ,  $-\text{L}_4\text{-E-aryl}$ ,  $-\text{C}(\text{O})\text{-alkyl}$ ,  $-\text{C}(\text{O})\text{-aryl}$ ,  $-\text{SO}_2\text{-alkyl}$ ,  $-\text{SO}_2\text{-aryl}$ , and



wherein

$\text{R}_9$ ,  $\text{R}_{10}$ , and  $\text{R}_{11}$  are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

$\text{L}_4$  is a direct bond, -alkylene, -alkenylene, or -alkynylene;

E is a direct bond,  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{N}(\text{R}_{12})-$ ,  $-\text{C}(\text{O})-$ ,  $-\text{CON}(\text{R}_{12})-$ ,  $-\text{N}(\text{R}_{12})\text{C}(\text{O})-$ ,  $-\text{N}(\text{R}_{12})\text{CON}(\text{R}_{13})-$ ,  $-\text{N}(\text{R}_{12})\text{C}(\text{O})\text{O}-$ ,  $-\text{OC}(\text{O})\text{N}(\text{R}_{12})-$ ,  $-\text{N}(\text{R}_{12})\text{SO}_2-$ ,  $-\text{SO}_2\text{N}(\text{R}_{12})-$ ,  $-\text{C}(\text{O})-\text{O}-$ ,  $-\text{O}-\text{C}(\text{O})-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ ,  $-\text{S}(\text{O}_2)-$ ,  $-\text{N}(\text{R}_{12})\text{SO}_2\text{N}(\text{R}_{13})-$ ,  $-\text{N}=\text{N}-$ , or  $-\text{N}(\text{R}_{12})-\text{N}(\text{R}_{13})-$


wherein

$R_{12}$  and  $R_{13}$  are independently selected from the group  
consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl,  
-alkylene-aryl, and -alkylene-arylene-alkyl;

$R_1$  is

- a) -hydrogen;
- b) -fluoro;
- c) -chloro;
- d) -bromo;
- e) -iodo;
- f) -cyano;
- g) -alkyl;
- h) -aryl;
- i) -alkylene-aryl;
- j) -heteroaryl;
- k) -alkylene-heteroaryl;
- l) -cycloalkyl;
- m) -alkylene-cycloalkyl
- n) - heterocyclyl; or
- o) - alkylene-heterocyclyl;

$L_1$  is selected from the group consisting of:



wherein  $R_3$  and  $R_4$  are independently selected from the group consisting of: hydrogen, chloro, fluoro, bromo, alkyl, aryl, -alkylene-aryl, -cycloalkyl, -alkylene-cycloalkyl, -heterocyclyl, -alkylene-heterocyclyl, and -alkynylene;

$\text{Ar}_1$  is an aryl, heteroaryl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, or fused heterocyclylheteroaryl a phenyl group optionally substituted 1 to 7-5 times wherein the substituents are independently selected from the group consisting of ;

- a)      -fluoro;
- b)      -chloro;
- c)      -bromo;
- d)      -iodo;
- e)      -cyano;
- f)      -nitro;
- g)      -perfluoroalkyl;
- h)      -J- $R_{14i}$ ;
- i)      -alkyl;
- j)      -aryl;
- k)      -heteroaryl;
- l)      -heterocyclyl;
- m)      -cycloalkyl;

- n) -L<sub>5</sub>-aryl;
- o) - L<sub>5</sub>-arylene-aryl;
- p) - L<sub>5</sub>-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -J-alkyl;
- t) -J-aryl;
- u) -J-alkylene-aryl;
- v) -J-arylene-alkyl;
- w) -J-alkylene-arylene-aryl;
- x) -J-arylene-arylene-aryl;
- y) -J-alkylene-arylene-alkyl;
- z) - L<sub>5</sub>-J-alkylene-aryl;
- aa) -arylene-J-alkyl;
- bb) - L<sub>5</sub>-J-aryl;
- cc) - L<sub>5</sub>-J-heteroaryl;
- dd) - L<sub>5</sub>-J-cycloalkyl;
- ee) - L<sub>5</sub>-J-heterocyclyl;
- ff) - L<sub>5</sub>-J-arylene-alkyl;
- gg) - L<sub>5</sub>-J-alkylene-arylene-alkyl;
- hh) - L<sub>5</sub>-J-alkyl;
- ii) - L<sub>5</sub>-J-R<sub>14</sub>; and
- jj) -arylene-J-R<sub>14</sub>;

wherein

L<sub>5</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

J is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>15</sub>)-, -C(O)-, -CON(R<sub>15</sub>)-, -N(R<sub>15</sub>)C(O)-, -N(R<sub>15</sub>)CON(R<sub>16</sub>)-, -N(R<sub>15</sub>)C(O)O-, -OC(O)N(R<sub>15</sub>)-, -N(R<sub>15</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>15</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>15</sub>)SO<sub>2</sub>N(R<sub>16</sub>)-, -N=N-, or -N(R<sub>15</sub>)-N(R<sub>16</sub>)-,

wherein

R<sub>14</sub>, R<sub>15</sub>, and R<sub>16</sub> are independently selected from a group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl

Ar<sub>2</sub> is an arylene, heteroarylene, fused arylcycloalkylene, fused cycloalkylarylene, fused cycloalkylheteroarylene, fused heterocyclylarylene, or fused heterocyclylheteroarylene; a phenyl group optionally substituted 1 to 5 times; wherein the substituents are independently selected from the group consisting of

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -Q-R<sub>17</sub>;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L<sub>6</sub>-aryl;
- o) -L<sub>6</sub>-arylene-aryl;
- p) -L<sub>6</sub>-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -Q-alkyl;
- t) -Q-aryl;
- u) -Q-alkylene-aryl;
- v) -Q-arylene-alkyl;
- w) -Q-alkylene-arylene-aryl;


- x) -Q-arylene-arylene-aryl;
- y) -Q-alkylene-arylene-alkyl;
- z) -L<sub>6</sub>-Q-alkylene-aryl;
- aa) -arylene-Q-alkyl;
- bb) -L<sub>6</sub>-Q-aryl;
- cc) -L<sub>6</sub>-Q-heteroaryl;
- dd) -L<sub>6</sub>-Q-cycloalkyl;
- ee) -L<sub>6</sub>-Q-heterocyclyl;
- ff) -L<sub>6</sub>-Q-arylene-alkyl;
- gg) -L<sub>6</sub>-Q-alkylene-arylene-alkyl;
- hh) -L<sub>6</sub>-Q-alkyl;
- ii) -L<sub>6</sub>-Q-alkylene-aryl-R<sub>17i</sub>;
- jj) -L<sub>6</sub>-Q-alkylene-heteroaryl-R<sub>17i</sub>;
- kk) -arylene-Q-alkylene-R<sub>17i</sub>;
- ll) -heteroarylene-Q-alkylene-R<sub>17i</sub>;
- mm) -L<sub>6</sub>-Q-aryl-R<sub>17i</sub>;
- nn) -L<sub>6</sub>-Q-heteroarylene-R<sub>17i</sub>;
- oo) -L<sub>6</sub>-Q-heteroaryl-R<sub>17i</sub>;
- pp) -L<sub>6</sub>-Q-cycloalkyl-R<sub>17i</sub>;
- qq) -L<sub>6</sub>-Q-heterocyclyl-R<sub>17i</sub>;
- rr) -L<sub>6</sub>-Q-arylene-alkyl-R<sub>17i</sub>;
- ss) -L<sub>6</sub>-Q-heteroarylene-alkyl-R<sub>17i</sub>;
- tt) -L<sub>6</sub>-Q-alkylene-arylene-alkyl-R<sub>17i</sub>;
- uu) -L<sub>6</sub>-Q-alkylene-heteroarylene-alkyl-R<sub>17i</sub>;
- vv) -L<sub>6</sub>-Q-alkylene-cycloalkylene-alkyl-R<sub>17i</sub>;
- ww) -L<sub>6</sub>-Q-alkylene-heterocyclylene-alkyl-R<sub>17i</sub>;
- xx) -L<sub>6</sub>-Q-alkyl-R<sub>17i</sub>;
- yy) -L<sub>6</sub>-Q-R<sub>17i</sub>;
- zz) -arylene-Q-R<sub>17i</sub>;





R<sub>18</sub> and R<sub>19</sub> are independently selected from the group consisting of: -  
hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and  
-alkylene-arylene-alkyl;

V is



Z is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl,  
-cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R<sub>17</sub> is -SO<sub>3</sub>H, -P(O)(OH)<sub>2</sub>, -P(O)(O-alkyl)(OH), -CO<sub>2</sub>H, -CO<sub>2</sub>-alkyl, an acid isostere,  
hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl

L<sub>2</sub> is selected from the group consisting of: ~~CH<sub>2</sub>, O, alkylene, alkenylene, alkynylene,~~  
~~-K-alkylene, -alkylene-K, -alkylene-K-alkylene, -alkenylene-K-alkylene, -alkylene-~~  
~~K-alkenylene, -arylene-K-alkylene, -alkylene-K-arylene, -heteroarylene-K-alkylene,~~  
~~alkylene-K-heteroarylene, -arylene-K, -K-arylene, -heteroarylene-K, -K-~~  
~~heteroarylene, and a direct bond,~~

wherein

~~K is a direct bond, N(R<sub>20</sub>), C(O), CON(R<sub>20</sub>), N(R<sub>20</sub>)C(O),~~  
~~N(R<sub>20</sub>)CON(R<sub>24</sub>), N(R<sub>20</sub>)C(O)O, OC(O)N(R<sub>20</sub>), N(R<sub>20</sub>)SO<sub>2</sub>,~~  
~~SO<sub>2</sub>N(R<sub>20</sub>), C(O)O, OC(O), S, S(O), S(O<sub>2</sub>), N(R<sub>20</sub>)SO<sub>2</sub>N(R<sub>24</sub>),~~  
~~N=N, or N(R<sub>20</sub>)N(R<sub>24</sub>); N(R<sub>20</sub>), C(O), CON(R<sub>20</sub>), N(R<sub>20</sub>)C(O),~~  
~~N(R<sub>20</sub>)CON(R<sub>24</sub>), N(R<sub>20</sub>)C(O)O, OC(O)N(R<sub>20</sub>), N(R<sub>20</sub>)SO<sub>2</sub>,~~  
~~SO<sub>2</sub>N(R<sub>20</sub>), C(O)O, OC(O), S, S(O), S(O<sub>2</sub>), N(R<sub>20</sub>)SO<sub>2</sub>N(R<sub>24</sub>),~~  
~~N=N, or N(R<sub>20</sub>)N(R<sub>24</sub>) or a direct bond,~~

wherein

~~R<sub>20</sub> and R<sub>24</sub> are independently selected from the group: hydrogen,  
-alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-  
alkyl;~~

~~T is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl,  
heteroaryl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, and  
fused heterocyclylheteroaryl~~a phenyl -group optionally substituted 1 to 7-5 times;  
wherein the substituents are independently selected from the group consisting of

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -U-R<sub>22</sub>;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L<sub>7</sub>-aryl;
- o) -L<sub>7</sub>-arylene-aryl;
- p) -L<sub>7</sub>-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -U-alkyl;
- t) -U-aryl;
- u) -U-alkylene-aryl;

- v) -U-arylene-alkyl;
- w) -U-alkylene-arylene-aryl;
- x) -U-arylene-arylene-aryl;
- y) -U-alkylene-arylene-alkyl;
- z) -L<sub>7</sub>-U-alkylene-aryl;
- aa) -arylene-U-alkyl;
- bb) -L<sub>7</sub>-U-aryl;
- cc) -L<sub>7</sub>-U-heteroaryl;
- dd) -L<sub>7</sub>-U-cycloalkyl;
- ee) -L<sub>7</sub>-U-heterocyclyl;
- ff) -L<sub>7</sub>-U-arylene-alkyl;
- gg) -L<sub>7</sub>-U-alkylene-arylene-alkyl;
- hh) -L<sub>7</sub>-U-alkyl;
- ii) -L<sub>7</sub>-U-alkylene-aryl- R<sub>22i</sub>;
- jj) -L<sub>7</sub>-U-alkylene-heteroaryl- R<sub>22i</sub>;
- kk) -arylene-U-alkylene- R<sub>22i</sub>;
- ll) -heteroarylene-U-alkylene- R<sub>22i</sub>;
- mm) -L<sub>7</sub>-U-aryl- R<sub>22i</sub>;
- nn) -L<sub>7</sub>-U-heteroarylene- R<sub>22i</sub>;
- oo) -L<sub>7</sub>-U-heteroaryl- R<sub>22i</sub>;
- pp) -L<sub>7</sub>-U-cycloalkyl- R<sub>22i</sub>;
- qq) -L<sub>7</sub>-U-heterocyclyl- R<sub>22i</sub>;
- rr) -L<sub>7</sub>-U-arylene-alkyl- R<sub>22i</sub>;
- ss) -L<sub>7</sub>-U-heteroarylene-alkyl- R<sub>22i</sub>;
- tt) -L<sub>7</sub>-U-alkylene-arylene-alkyl- R<sub>22i</sub>;
- uu) -L<sub>7</sub>-U-alkylene-heteroarylene-alkyl- R<sub>22i</sub>;
- vv) -L<sub>7</sub>-Q-alkylene-cycloalkylene-alkyl-R<sub>22i</sub>;
- ww) -L<sub>7</sub>-Q-alkylene-heterocyclylene-alkyl-R<sub>22i</sub>;
- xx) -L<sub>7</sub>-U-alkyl- R<sub>22i</sub>;

yy) -L<sub>7</sub>-U- R<sub>22</sub>;

zz) -arylene-U- R<sub>22</sub>;

aaa) -heteroarylene-U- R<sub>22</sub>;

bbb) -heterocyclylene-U- R<sub>22</sub>;

ccc) -U-alkylene- R<sub>22</sub>;

ddd) -U-arylene- R<sub>22</sub>;

eee) -U-heteroarylene- R<sub>22</sub>;

fff) -U-alkylene-arylene- R<sub>22</sub>;

ggg) -U-alkylene-heteroarylene- R<sub>22</sub>;

hhh) -U-heteroarylene-alkylene- R<sub>22</sub>;



iii) -U-arylene-alkylene- R<sub>22</sub>;

jjj) -U-cycloalkylene-alkylene- R<sub>22</sub>;

kkk) -U-heterocyclylene-alkylene- R<sub>22</sub>;

lll) -U-alkylene-arylene-alkyl- R<sub>22</sub>;

mmm) -U-alkylene-heteroarylene-alkyl- R<sub>22</sub>;



wherein


L<sub>7</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

U is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>23</sub>)-, -C(O)-, -CON(R<sub>23</sub>)-, -N(R<sub>23</sub>)C(O)-, -N(R<sub>23</sub>)CON(R<sub>24</sub>)-, -N(R<sub>23</sub>)C(O)O-, -OC(O)N(R<sub>23</sub>)-, -N(R<sub>23</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>23</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>23</sub>)SO<sub>2</sub>N(R<sub>24</sub>)-, -N=N-, or -N(R<sub>23</sub>)-N(R<sub>24</sub>)-;

wherein

R<sub>23</sub> and R<sub>24</sub> are independently selected from the group consisting of: -  
hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-  
arylene-alkyl;

X is



Y is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl,  
-cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R<sub>22</sub> is -SO<sub>3</sub>H, -P(O)(OH)<sub>2</sub>, -P(O)(O-alkyl)(OH), -CO<sub>2</sub>H, -CO<sub>2</sub>-alkyl, an acid isostere,  
-hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl;


or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

2. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein W is ~~—O—~~ or ~~—N(R<sub>2</sub>)—~~, wherein R<sub>2</sub> is hydrogen, alkyl, or ~~—L<sub>3</sub>—D—~~alkylene-aryl, wherein L<sub>3</sub> is alkylene, and D is ~~—CO(NR<sub>5</sub>)—~~, wherein R<sub>5</sub> is hydrogen.

3. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R<sub>1</sub> is hydrogen or aryl.


4. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R<sub>1</sub> is hydrogen.

5. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein L<sub>1</sub> is



6. (Previously Presented) The compound of Formula (I) according to claim

1 or a pharmaceutically acceptable salt thereof, wherein  $L_1$  is



7. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein  $Ar_1$  is a phenyl or naphthyl-group optionally having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -J- $R_{14}$ ;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) - $L_5$ -aryl;
- o) -  $L_5$ -arylene-aryl;
- p) -  $L_5$ -arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -J-alkyl;
- t) -J-aryl;
- u) -J-alkylene-aryl;

- v) -J-arylene-alkyl;
- w) -J-alkylene-arylene-aryl;
- x) -J-arylene-arylene-aryl;
- y) -J-alkylene-arylene-alkyl;
- z) -L<sub>5</sub>-J-alkylene-aryl;
- aa) -arylene-J-alkyl;
- bb) -L<sub>5</sub>-J-aryl;
- cc) -L<sub>5</sub>-J-heteroaryl;
- dd) -L<sub>5</sub>-J-cycloalkyl;
- ee) -L<sub>5</sub>-J-heterocyclyl;
- ff) -L<sub>5</sub>-J-arylene-alkyl;
- gg) -L<sub>5</sub>-J-alkylene-arylene-alkyl;
- hh) -L<sub>5</sub>-J-alkyl;
- ii) -L<sub>5</sub>-J-R<sub>14</sub>; and
- jj) -arylene-J-R<sub>14</sub>; and

~~kk)-hydrogen;~~

wherein

L<sub>5</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

J is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>15</sub>)-, -C(O)-, -CON(R<sub>15</sub>)-, -N(R<sub>15</sub>)C(O)-, -N(R<sub>15</sub>)CON(R<sub>16</sub>)-, -N(R<sub>15</sub>)C(O)O-, -OC(O)N(R<sub>15</sub>)-, -N(R<sub>15</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>15</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>15</sub>)SO<sub>2</sub>N(R<sub>16</sub>)-, -N=N-, or -N(R<sub>15</sub>)-N(R<sub>16</sub>)-,

wherein

R<sub>14</sub>, R<sub>15</sub>, and R<sub>16</sub> are independently selected from a group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl.

8. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>1</sub> is a phenyl group optionally



substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro; and
- g) -aryl.


9. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>1</sub> is a phenyl group substituted 1 to 5 times, wherein the substituents are selected from the group consisting of: -chloro and -fluoro.


10. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>2</sub> is a phenylene or naphthylene group optionally having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -Q-R<sub>17</sub>;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;

- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L<sub>6</sub>-aryl;
- o) -L<sub>6</sub>-arylene-aryl;
- p) -L<sub>6</sub>-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -Q-alkyl;
- t) -Q-aryl;
- u) -Q-alkylene-aryl;
- v) -Q-arylene-alkyl;
- w) -Q-alkylene-arylene-aryl;
- x) -Q-arylene-arylene-aryl;
- y) -Q-alkylene-arylene-alkyl;
- z) -L<sub>6</sub>-Q-alkylene-aryl;
- aa) -arylene-Q-alkyl;
- bb) -L<sub>6</sub>-Q-aryl;
- cc) -L<sub>6</sub>-Q-heteroaryl;
- dd) -L<sub>6</sub>-Q-cycloalkyl;
- ee) -L<sub>6</sub>-Q-heterocyclyl;
- ff) -L<sub>6</sub>-Q-arylene-alkyl;
- gg) -L<sub>6</sub>-Q-alkylene-arylene-alkyl;
- hh) -L<sub>6</sub>-Q-alkyl;
- ii) -L<sub>6</sub>-Q-alkylene-aryl-R<sub>17</sub>;
- jj) -L<sub>6</sub>-Q-alkylene-heteroaryl-R<sub>17</sub>;
- kk) -arylene-Q-alkylene-R<sub>17</sub>;
- ll) -heteroarylene-Q-alkylene-R<sub>17</sub>;
- mm) -L<sub>6</sub>-Q-aryl-R<sub>17</sub>;
- nn) -L<sub>6</sub>-Q-heteroarylene-R<sub>17</sub>;

- oo) -L<sub>6</sub>-Q-heteroaryl-R<sub>17</sub>;
- pp) -L<sub>6</sub>-Q-cycloalkyl-R<sub>17</sub>;
- qq) -L<sub>6</sub>-Q-heterocyclyl-R<sub>17</sub>;
- rr) -L<sub>6</sub>-Q-arylene-alkyl-R<sub>17</sub>;
- ss) -L<sub>6</sub>-Q-heteroarylene-alkyl-R<sub>17</sub>;
- tt) -L<sub>6</sub>-Q-alkylene-arylene-alkyl-R<sub>17</sub>;
- uu) -L<sub>6</sub>-Q-alkylene-heteroarylene-alkyl-R<sub>17</sub>;
- vv) -L<sub>6</sub>-Q-alkylene-cycloalkylene-alkyl-R<sub>17</sub>;
- ww) -L<sub>6</sub>-Q-alkylene-heterocyclylene-alkyl-R<sub>17</sub>;
- xx) -L<sub>6</sub>-Q-alkyl-R<sub>17</sub>;
- yy) -L<sub>6</sub>-Q-R<sub>17</sub>;
- zz) -arylene-Q-R<sub>17</sub>;
- aaa) -heteroarylene-Q-R<sub>17</sub>;
- bbb) -heterocyclylene-Q-R<sub>17</sub>;
- ccc) -Q-alkylene-R<sub>17</sub>;
- ddd) -Q-arylene-R<sub>17</sub>;
- eee) -Q-heteroarylene-R<sub>17</sub>;
- fff) -Q-alkylene-arylene-R<sub>17</sub>;
- ggg) -Q-alkylene-heteroarylene-R<sub>17</sub>;
- hhh) -Q-heteroarylene-alkylene- R<sub>17</sub>;
- iii) -Q-arylene-alkylene- R<sub>17</sub>;
- jjj) -Q-cycloalkylene-alkylene- R<sub>17</sub>;
- kkk) -Q-heterocyclylene-alkylene- R<sub>17</sub>;
- lll) -Q-alkylene-arylene-alkyl- R<sub>17</sub>;
- mmm) -Q-alkylene-heteroarylene-alkyl- R<sub>17</sub>;





~~ppp)~~ hydrogen

wherein


$L_6$  is a direct bond, -alkylene, -alkenylene, or -alkynylene;

Q is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>18</sub>)-, -C(O)-, -CON(R<sub>18</sub>)-, -N(R<sub>18</sub>)C(O)-, -N(R<sub>18</sub>)CON(R<sub>19</sub>)-, -N(R<sub>18</sub>)C(O)O-, -OC(O)N(R<sub>18</sub>)-, -N(R<sub>18</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>18</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>18</sub>)SO<sub>2</sub>N(R<sub>19</sub>)-, -N=N-, or -N(R<sub>18</sub>)-N(R<sub>19</sub>)-;

wherein

R<sub>18</sub> and R<sub>19</sub> are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

V is



Z is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R<sub>17</sub> is -SO<sub>3</sub>H, -P(O)(OH)<sub>2</sub>, -P(O)(O-alkyl)(OH), -CO<sub>2</sub>H, -CO<sub>2</sub>-alkyl, an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

11. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>2</sub> is a phenyl group ~~or naphthyl~~

group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -Q-R<sub>17</sub>;
- f) -alkyl;
- g) -aryl;
- h) -arylene-alkyl;
- i) -Q-alkyl; and
- j) -arylene-Q-alkyl;

wherein

Q is -CH<sub>2</sub>-, -O-, -C(O)-, or -C(O)-O-, and

R<sub>17</sub> is: -hydrogen, -alkyl, -aryl, -CO<sub>2</sub>H, or an acid isostere.

12. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>2</sub> is a phenyl group substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -Q-R<sub>17</sub>;
- f) -alkyl;
- g) -phenyl;
- h) -phenylene-alkyl;
- i) -Q-alkyl; and

j) -phenylene-Q-alkyl;

wherein

Q is:  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{C}(\text{O})-$ , or  $-\text{C}(\text{O})-\text{O}-$ , and

$\text{R}_{17}$  is: -hydrogen, -alkyl, -phenyl, or  $-\text{CO}_2\text{H}$ .



13-15. (Canceled)

16. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein T is an aryl group optionally having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h)  $-\text{U}-\text{R}_{22}$ ;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n)  $-\text{L}_7$ -aryl;
- o)  $-\text{L}_7$ -arylene-aryl;
- p)  $-\text{L}_7$ -arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;

- s) -U-alkyl;
- t) -U-aryl;
- u) -U-alkylene-aryl;
- v) -U-arylene-alkyl;
- w) -U-alkylene-arylene-aryl;
- x) -U-arylene-arylene-aryl;
- y) -U-alkylene-arylene-alkyl;
- z) -L<sub>7</sub>-U-alkylene-aryl;
- aa) -arylene-U-alkyl;
- bb) -L<sub>7</sub>-U-aryl;
- cc) -L<sub>7</sub>-U-heteroaryl;
- dd) -L<sub>7</sub>-U-cycloalkyl;
- ee) -L<sub>7</sub>-U-heterocyclyl;
- ff) -L<sub>7</sub>-U-arylene-alkyl;
- gg) -L<sub>7</sub>-U-alkylene-arylene-alkyl;
- hh) -L<sub>7</sub>-U-alkyl;
- ii) -L<sub>7</sub>-U-alkylene-aryl- R<sub>22</sub>;
- jj) -L<sub>7</sub>-U-alkylene-heteroaryl- R<sub>22</sub>;
- kk) -arylene-U-alkylene- R<sub>22</sub>;
- ll) -heteroarylene-U-alkylene- R<sub>22</sub>;
- mm) -L<sub>7</sub>-U-aryl- R<sub>22</sub>;
- nn) -L<sub>7</sub>-U-heteroarylene- R<sub>22</sub>;
- oo) -L<sub>7</sub>-U-heteroaryl- R<sub>22</sub>;
- pp) -L<sub>7</sub>-U-cycloalkyl- R<sub>22</sub>;
- qq) -L<sub>7</sub>-U-heterocyclyl- R<sub>22</sub>;
- rr) -L<sub>7</sub>-U-arylene-alkyl- R<sub>22</sub>;
- ss) -L<sub>7</sub>-U-heteroarylene-alkyl- R<sub>22</sub>;
- tt) -L<sub>7</sub>-U-alkylene-arylene-alkyl- R<sub>22</sub>;
- uu) -L<sub>7</sub>-U-alkylene-heteroarylene-alkyl- R<sub>22</sub>;

- vv)  $-L_7-Q\text{-alkylene-cycloalkylene-alkyl-}R_{22}$ ;  
ww)  $-L_7-Q\text{-alkylene-heterocyclylene-alkyl-}R_{22}$ ;  
xx)  $-L_7-U\text{-alkyl-}R_{22}$ ;  
yy)  $-L_7-U\text{-}R_{22}$ ;  
zz)  $\text{-arylene-U-}R_{22}$ ;  
aaa)  $\text{-heteroarylene-U-}R_{22}$ ;  
bbb)  $\text{-heterocyclylene-U-}R_{22}$ ;  
ccc)  $\text{-U-alkylene-}R_{22}$ ;  
ddd)  $\text{-U-arylene-}R_{22}$ ;  
eee)  $\text{-U-heteroarylene-}R_{22}$ ;  
fff)  $\text{-U-alkylene-arylene-}R_{22}$ ;  
ggg)  $\text{-U-alkylene-heteroarylene-}R_{22}$ ;  
hhh)  $\text{-U-heteroarylene-alkylene-}R_{22}$ ;  
iii)  $\text{-U-arylene-alkylene-}R_{22}$ ;  
jjj)  $\text{-U-cycloalkylene-alkylene-}R_{22}$ ;  
kkk)  $\text{-U-heterocyclylene-alkylene-}R_{22}$ ;  
lll)  $\text{-U-alkylene-arylene-alkyl-}R_{22}$ ;  
mmm)  $\text{-U-alkylene-heteroarylene-alkyl-}R_{22}$ ;



~~ppp) hydrogen;~~

wherein

$L_7$  is a direct bond,  $\text{-alkylene}$ ,  $\text{-alkenylene}$ , or  $\text{-alkynylene}$ ;

U is a direct bond,  $\text{-CH}_2\text{-}$ ,  $\text{-O-}$ ,  $\text{-N(R}_{23}\text{)-}$ ,  $\text{-C(O)-}$ ,  $\text{-CON(R}_{23}\text{)-}$ ,  $\text{-N(R}_{23}\text{)C(O)-}$ ,  
 $\text{-N(R}_{23}\text{)CON(R}_{24}\text{)-}$ ,  $\text{-N(R}_{23}\text{)C(O)O-}$ ,  $\text{-OC(O)N(R}_{23}\text{)-}$ ,  $\text{-N(R}_{23}\text{)SO}_2\text{-}$ , -




$\text{SO}_2\text{N}(\text{R}_{23})-$ ,  $-\text{C}(\text{O})-\text{O}-$ ,  $-\text{O}-\text{C}(\text{O})-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ ,  $-\text{S}(\text{O}_2)-$ ,  $-\text{N}(\text{R}_{23})\text{SO}_2\text{N}(\text{R}_{24})-$ ,  $-\text{N}=\text{N}-$ , or  $-\text{N}(\text{R}_{23})-\text{N}(\text{R}_{24})-$ ;

wherein

$\text{R}_{23}$  and  $\text{R}_{24}$  are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

X is




Y is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

$\text{R}_{22}$  is  $-\text{SO}_3\text{H}$ ,  $-\text{P}(\text{O})(\text{OH})_2$ ,  $-\text{P}(\text{O})(\text{O-alkyl})(\text{OH})$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{-alkyl}$ , an acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

17. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein T is an aryl group substituted by -U-alkylene- $\text{R}_{22}$ , wherein U is -O- or a direct bond, and  $\text{R}_{22}$  is  $-\text{CO}_2\text{H}$  or an acid isostere.

18. (Currently Amended) The compound of Formula (I) according to claim 16 or a pharmaceutically acceptable salt thereof, wherein

a and b are equal to zero;



Ar<sub>2</sub> is a phenylene group optionally substituted 1 time with a group consisting of:  
-Q-alkyl, wherein Q is -O-;

L<sub>2</sub> is a direct bond, ~~O-alkylene, or an-alkynylene~~; and

T is an aryl group substituted with at least one substituent selected from the group consisting of:

- a) -U-R<sub>22</sub>;
- b) -U-alkylene-arylene-R<sub>22</sub>;
- c) -U-alkylene-R<sub>22</sub>;
- d) -U-arylene-R<sub>22</sub>;
- e) -U-arylene-R<sub>22</sub> wherein the arylene is substituted with at least one of a halogen, methanesulfonylamino, or trifluoromethanesulfonylamino group;
- f) -U-arylene wherein the arylene is substituted with at least one trifluoromethanesulfonylamino group;
- g) -R<sub>22</sub>; and
- h) -halogen<sub>i</sub>

wherein R<sub>22</sub> is -CO<sub>2</sub>H or an acid isotere.

19. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

a and b are equal to zero;

R<sub>1</sub> is hydrogen;

W is -N(R<sub>2</sub>)-, wherein R<sub>2</sub> is alkyl; and

Ar<sub>1</sub> is ~~aryl~~-phenyl substituted 2 times wherein the substituent groups are -chloro.

20. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein W is -N(R<sub>2</sub>)-, wherein R<sub>2</sub> is - L<sub>3</sub>-D-alkylene-arylene-G, wherein L<sub>3</sub> is a direct bond or alkylene, D is a direct bond, or -O-,

and G is  $-\text{CN}$ ,  $-\text{SO}_3\text{H}$ ,  $-\text{P}(\text{O})(\text{OH})_2$ ,  $-\text{P}(\text{O})(\text{O-alkyl})(\text{OH})$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{-alkyl}$ , or an acid isostere.

21. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein a and b are equal to 0, and T,  $\text{L}_2$ ,  $\text{Ar}_2$ , and  $\text{L}_1$  together form a group selected from a group consisting of:

(E)-2-(4-methoxyphenyl)vinyl, (E)-2-(3-methoxyphenyl)vinyl, (E)-2-(2-methoxyphenyl)vinyl, (E)-2-(3,4-dimethoxyphenyl)vinyl, (E)-2-(2,3,4-trimethoxyphenyl)vinyl, (E)-2-(4-ethoxyphenyl)vinyl, (E)-2-phenylvinyl, (E)-2-(4-fluorophenyl)vinyl, (E)-2-(4-chlorophenyl)vinyl, (E)-2-(4-bromophenyl)vinyl, (E)-2-(1,1'-biphenyl-4-yl)vinyl, (E)-2-(1-naphthyl)vinyl, (E)-2-(2-naphthyl)vinyl, 9H-fluoren-9-ylidenemethyl, (E)-2-(4'-methoxy-1,1'-biphenyl-4-yl)vinyl, (E)-2-(3'-methoxy-1,1'-biphenyl-4-yl)vinyl, (E)-2-(4-hydroxyphenyl)vinyl, 2-(4-methoxyphenyl)ethyl, (E)-2-(4'-carboxymethyloxy-1,1'-biphenyl-4-yl)vinyl, (E)-2-(4'-(3-methoxycarbonyl-1-propyloxy)-1,1'-biphenyl-4-yl)vinyl, (E)-2-(4'-(3-carboxy-1-propyloxy)-1,1'-biphenyl-4-yl)vinyl, (E)-2-(4'-phenoxy-1,1'-biphenyl-4-yl)vinyl, and (E)-2-(4'-benzyloxy-1,1'-biphenyl-4-yl)vinyl.

22. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein  $\text{Ar}_1$  is: 2,4-dichlorophenyl.

23. (Currently Amended) The compound of Formula (I) according to claim 1, where the compound of Formula (I) is:

4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-3-fluoro-biphenyl-4-yloxymethyl)-benzoic acid;

4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-phenoxy-methyl)-benzoic acid;

4-[4'-(2-[4-(2,4-dichloro-phenyl)-1-[(1-naphthalen-1-yl-ethylcarbamoyl)-methyl]1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy]-butyric acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-butyric acid;

~~5-[3-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-propyl]-1H-tetrazole;~~

[4-(3-(2-[4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]-(E)-vinyl)-4-methoxy-phenyl-ethynyl)-phenoxy]-acetic acid;

4-[3-(4-(2-[4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]-(E)-vinyl)-phenylethynyl)-phenoxy]-butyric acid;

~~5-[3-(4'-(2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-propyl]-1H-tetrazole;~~

5-(4'-(2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-pentanoic acid

2-bromo-4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-benzoic acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxymethyl)-benzoic acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-benzoic acid;

2-bromo-4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-benzoic acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-3-methanesulfonylamino-benzoic acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-3-trifluoromethanesulfonyl-amino-benzoic acid;

5-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-2-methanesulfonylamino-benzoic acid;

5-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-2-trifluoromethane-sulfonylamino-benzoic acid; or

4-(4'-{2-[4-(2,4-Dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-butyric acid 2,2-dimethyl-propionyloxymethyl ester,  
or a pharmaceutically acceptable salt thereof.

24. (Currently Amended) A pharmaceutical composition comprising a—a compound as claimed in claim 1.

25. (Previously Presented) The pharmaceutical composition of claim 24, wherein said pharmaceutical composition is a topical formulation.

26. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in Claim 1 sufficient to inhibit protein tyrosine phosphatase.

27. (Original) The pharmaceutical composition of claim 26, in the form of an oral dosage or parenteral dosage unit.

28. (Original) The pharmaceutical composition of claim 26, wherein said compound is administered as a dose in a range from about 0.003 to 500 mg/kg of body weight per day.

29. (Original) The pharmaceutical composition of claim 26, wherein said compound is administered as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

30. (Original) The pharmaceutical composition of claim 26, wherein said compound is administered as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

31. (Previously Presented) The pharmaceutical composition of claim 26, further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, acarbose, PPAR agonists, DPP-IV inhibitors, GK activators, insulin, insulin mimetics, insulin secretagogues, insulin sensitizers, GLP-1, GLP-1 mimetics, cholinesterase inhibitors, antipsychotics, antidepressants, anticonvulsants, HMG CoA reductase inhibitors, cholestyramine, and fibrates.

32. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type I diabetes.

33. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type II diabetes.

34-37. (Canceled).

38. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat obesity.

39. (Canceled).

40. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat psoriasis.

41-46. (Canceled)

47. (Withdrawn) A method of inhibition protein tyrosine phosphatases which comprises administering to a subject in need thereof a pharmacologically effective amount of a compound as claimed in claim 1.

48. (Withdrawn) A method of prevention and/or treatment of PTPase mediated human diseases, treatment comprising alleviation of one or more symptoms resulting from that disorder, to an outright cure for that particular disorder or prevention of the onset of the disorder, the method comprising administration to a human in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

49. (Withdrawn) The method of claim 47, further comprising administering to a subject in need thereof at least one adjuvant and/or additional therapeutic agent(s).

50. (Withdrawn) A method of treating PTPase mediated diseases, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a compound as claimed in claim 1, in combination with one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, acarbose, PPAR agonists, DPP-IV inhibitors, GK activators, insulin, insulin mimetics, insulin secretagogues, insulin sensitizers, GLP-1, GLP-1 mimetics, cholinesterase inhibitors, antipsychotics, antidepressants, anticonvulsants, HMG CoA reductase inhibitors, cholestyramine, and fibrates.

51. (Withdrawn) A method for treating acute and/or chronic inflammation, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

52. (Withdrawn) A method for treating type I or type II diabetes, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

53. (Withdrawn) A method for treating immune dysfunction, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

54. (Withdrawn) A method for treating AIDS, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

55. (Withdrawn) A method for treating autoimmune disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

56. (Withdrawn) A method for treating glucose intolerance, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

57. (Withdrawn) A method for treating cancer, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

58. (Withdrawn) A method for treating psoriasis, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

59. (Withdrawn) A method for treating allergic diseases, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

60. (Withdrawn) A method for treating infectious disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.



61. (Withdrawn) A method for treating diseases involving the modulated synthesis of growth hormone, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

62. (Withdrawn) A method for treating modulated synthesis of growth factors or cytokines which affect the production of growth hormone, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.

63. (Withdrawn) A method for treating Alzheimer's disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1.